Safety and Efficacy of Immunoadsorption As an Add-On to Medical Treatment in Patients with Severe Idiopathic Pulmonary Arterial Hypertension

Overview

Journal Respiration

Publisher Karger

Specialty Pulmonary Medicine

Date 2017 Aug 9

PMID 28787715

Citations 2

Authors

Christian Nagel

Ralf Ewert

Benjamin Egenlauf

Hans B Lehmkuhl

Stephan Rosenkranz

Nicola Benjamin

Vedat Schwenger

Felix J F Herth

Ekkehard Grunig

Affiliations

Soon will be listed here.

Abstract

Background: Despite optimized medical therapy, severe idiopathic pulmonary arterial hypertension (IPAH) is a devastating disease with a poor outcome. Autoantibodies have been detected in IPAH that can contribute to worsening of the disease.

Objectives: The objective of this prospective, open-label, single-arm, multicenter trial was to evaluate the safety and efficacy of immunoadsorption (IA) as an add-on to optimized medical treatment for patients with IPAH.

Methods: A total of 10 IPAH patients received IA over 5 days. Their clinical parameters, including hemodynamics measured by right heart catheter, were assessed at baseline and after 3 and 6 months. The primary endpoint was the change in pulmonary vascular resistance (PVR). Secondary endpoints included the change in 6-min walking distance, quality of life, safety, and plasma levels of IgG and autoantibodies.

Results: The evaluation of the 10 IPAH patients (75% female; 51 ± 12 years; 166 ± 10 cm; WHO functional class III; 53% on combination therapy) revealed that IA was a safe procedure that efficiently removed IgG and autoantibodies from the circulation. After 3 months, the mean PVR improved significantly by 13.2% (p = 0.03) and the cardiac index improved by 13.1%, but no significant changes were found in 6-min walking distance. The quality of life physical functioning subscale score significantly improved after 6 months. The serious adverse events in 3 patients were possibly related to IA and included pneumonia, temporary disturbance in attention, and thrombocytopenia.

Conclusions: IA as an add-on to targeted medical treatment for IPAH is a safe procedure with beneficial effects on hemodynamics, especially in patients with high levels of autoantibodies. Larger-scale controlled studies are needed to assess its efficacy in IPAH and to identify responders.

Citing Articles

B-cells in pulmonary arterial hypertension: friend, foe or bystander?.

Sanges S, Tian W, Dubucquoi S, Chang J, Collet A, Launay D Eur Respir J. 2024; 63(4).

PMID: 38485150 PMC: 11043614. DOI: 10.1183/13993003.01949-2023.

Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report.

Kreidy M, Al-Hilli A, Yachoui R, Resnick J BMC Pulm Med. 2020; 20(1):8.

PMID: 31918690 PMC: 6953266. DOI: 10.1186/s12890-019-1020-6.

References

Groth A, Vrugt B, Brock M, Speich R, Ulrich S, Huber L . Inflammatory cytokines in pulmonary hypertension. Respir Res. 2014; 15:47. PMC: 4002553. DOI: 10.1186/1465-9921-15-47. View

Dandel M, Jasaityte R, Lehmkuhl H, Knosalla C, Hetzer R . Maintenance immunosuppression with mycophenolate mofetil: long-term efficacy and safety after heart transplantation. Transplant Proc. 2009; 41(6):2585-8. DOI: 10.1016/j.transproceed.2009.06.031. View

Staudt A, Schaper F, Stangl V, Plagemann A, Bohm M, Merkel K . Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation. 2001; 103(22):2681-6. DOI: 10.1161/01.cir.103.22.2681. View

Staudt A, Staudt Y, Hummel A, Empen K, Dorr M, Trimpert C . Effects of immunoadsorption on the nt-BNP and nt-ANP plasma levels of patients suffering from dilated cardiomyopathy. Ther Apher Dial. 2006; 10(1):42-8. DOI: 10.1111/j.1744-9987.2006.00343.x. View

Gazdic T, Malek I, Pagacova L, Slavcev A, Voska L, Hegarova M . Safety and Efficacy of Immunoadsorption in Heart Transplantation Program. Transplant Proc. 2016; 48(8):2792-2796. DOI: 10.1016/j.transproceed.2016.06.061. View

Hoffmann J, Yin J, Kukucka M, Yin N, Saarikko I, Sterner-Kock A . Mast cells promote lung vascular remodelling in pulmonary hypertension. Eur Respir J. 2010; 37(6):1400-10. DOI: 10.1183/09031936.00043310. View

Colvin K, Cripe P, Ivy D, Stenmark K, Yeager M . Bronchus-associated lymphoid tissue in pulmonary hypertension produces pathologic autoantibodies. Am J Respir Crit Care Med. 2013; 188(9):1126-36. PMC: 3863738. DOI: 10.1164/rccm.201302-0403OC. View

Dib H, Tamby M, Bussone G, Regent A, Berezne A, Lafine C . Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J. 2011; 39(6):1405-14. DOI: 10.1183/09031936.00181410. View

Ware Jr J, Sherbourne C . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30(6):473-83. View

10.

Price L, Wort S, Perros F, Dorfmuller P, Huertas A, Montani D . Inflammation in pulmonary arterial hypertension. Chest. 2012; 141(1):210-221. DOI: 10.1378/chest.11-0793. View

11.

Guyatt G, Pugsley S, Sullivan M, Thompson P, Berman L, Jones N . Effect of encouragement on walking test performance. Thorax. 1984; 39(11):818-22. PMC: 459930. DOI: 10.1136/thx.39.11.818. View

12.

Dandel M, Wallukat G, Englert A, Hetzer R . Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension. Atheroscler Suppl. 2013; 14(1):203-11. DOI: 10.1016/j.atherosclerosissup.2012.10.029. View

13.

Bussone G, Tamby M, Calzas C, Kherbeck N, Sahbatou Y, Sanson C . IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Ann Rheum Dis. 2011; 71(4):596-605. DOI: 10.1136/annrheumdis-2011-200195. View

14.

Jensen L, Marchant D . Emerging pharmacologic targets and treatments for myocarditis. Pharmacol Ther. 2016; 161:40-51. DOI: 10.1016/j.pharmthera.2016.03.006. View

15.

El Kasmi K, Pugliese S, Riddle S, Poth J, Anderson A, Frid M . Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension. J Immunol. 2014; 193(2):597-609. PMC: 4100597. DOI: 10.4049/jimmunol.1303048. View

16.

Grunig G, Marsh L, Esmaeil N, Jackson K, Gordon T, Reibman J . Perspective: ambient air pollution: inflammatory response and effects on the lung's vasculature. Pulm Circ. 2014; 4(1):25-35. PMC: 4070766. DOI: 10.1086/674902. View

17.

Staudt A, Bohm M, Knebel F, Grosse Y, Bischoff C, Hummel A . Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation. 2002; 106(19):2448-53. DOI: 10.1161/01.cir.0000036746.49449.64. View

18.

Becker L, Siebert D, Susal C, Opelz G, Leo A, Waldherr R . Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption. Transplantation. 2015; 99(11):2364-71. DOI: 10.1097/TP.0000000000000753. View

19.

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

20.

Trimpert C, Herda L, Eckerle L, Pohle S, Muller C, Landsberger M . Immunoadsorption in dilated cardiomyopathy: long-term reduction of cardiodepressant antibodies. Eur J Clin Invest. 2010; 40(8):685-91. DOI: 10.1111/j.1365-2362.2010.02314.x. View